Anti-Sarilumab ELISA Kit

Catalog No.

KAC36902

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative sandwich enzyme immunoassay technique. Sarilumab has been pre-coated onto a microplate. Samples or standards are pipetted into microwells and Anti-Sarilumab will be captured by immobilized Sarilumab. After washing away any unbound substances, a biotin-labeled Sarilumab is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Anti-Sarilumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Anti-Sarilumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

0.78 -50 ng/mL

Sensitivity

0.46 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <10%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <15%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	26.3	5.9	1.2	22.4	5.7	1.3
Standard deviation	1.3	0.6	0.1	1.4	0.4	0.2
CV (%)	4.8	9.9	9.9	6.3	6.6	14.5

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

REGN88,SAR153191, CAS: 1189541-98-7

Sarilumab in the treatment of rheumatoid arthritis: future perspectives., PMID:40506803

New treatments for systemic mastocytosis in 2025., PMID:40471046

Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis., PMID:40393718

Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial., PMID:40360262

Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment., PMID:40142915

Cost-effectiveness analysis of subcutaneous biosimilar tocilizumab in patients with rheumatoid arthritis in Spain., PMID:40113553

Population Pharmacokinetics and Exposure-Response Analyses of Sarilumab in Patients with Polymyalgia Rheumatica., PMID:40105153

Successful Salvage Therapy of Late-onset Arterial Disorders due to Recurrent Vasospasms Following Free Flap Transfer under the IL-6 and TNF-α Signaling-downregulated Environment: A Case Report., PMID:40104165

Anti-Rheumatic potential of biological DMARDS and protagonistic role of bio-markers in early detection and management of rheumatoid arthritis., PMID:40091354

Advances in the treatment of polymyalgia rheumatica., PMID:40071422

Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study., PMID:40055759

Interleukin 6 inhibition in refractory antisynthetase syndrome: case-based literature review., PMID:40053413

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)., PMID:40044198

Nontraumatic terminal ileal perforation in a patient with resistant palindromic rheumatism treated with sarilumab: A case report., PMID:40024808

Effectiveness of baricitinib versus sarilumab on disease activity in patients with RA: a propensity score matching study., PMID:39959132

[Rheumatology: what's new in 2024]., PMID:39881648

Terminal complement complex deposition on chondrocytes promotes premature senescence in age- and trauma-related osteoarthritis., PMID:39877352

Safety and Efficacy of Baricitinib, Upadacitinib, and Sarilumab Implementation in Moderately-to-Severely Active Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Current Evidence., PMID:39867028

IL-6R Inhibitors and Gastrointestinal Perforations: A Pharmacovigilance Study and a Predicting Nomogram., PMID:39767766

Successful Remission of Refractory Rheumatoid Pleural Effusion and Arthritis Using Sarilumab: A Case Report., PMID:39744302

Long-term efficacy of sarilumab on the progression of interstitial lung disease in rheumatoid arthritis: the KEIO-RA cohort and literature review., PMID:39711360

The pattern of anti-IL-6 versus non-anti-IL-6 biologic disease modifying anti-rheumatic drugs use in patients with rheumatoid arthritis in Wales, UK: a real-world study using electronic health records., PMID:39698233

Cost-effectiveness analysis of subcutaneous biosimilar tocilizumab in patients with rheumatoid arthritis in Spain., PMID:39675937

Rates of glucocorticoid taper in the management of polymyalgia rheumatica: the science behind the "art"., PMID:39641835

A Glimpse for the subsistence from pandemic SARS-CoV-2 infection., PMID:39603070

Leveraging large-scale multi-omics evidences to identify therapeutic targets from genome-wide association studies., PMID:39563277

Evaluating Meaningful Changes in Patient-Reported Outcome Measurement Information System-Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Patients With Rheumatoid Arthritis., PMID:39545383

Traditional and Emerging Strategies for Managing Polymyalgia Rheumatica: Insights into New Treatments., PMID:39518631

Biological and Therapeutic Role of Interleukin-6 in Non-Infectious Uveitis: A Narrative Review., PMID:39404707

Evaluating anchor variables and variation in meaningful score differences for PROMIS® Pediatric measures in children and adolescents living with a rheumatic disease., PMID:39400691

Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study., PMID:39287897

A case of VEXAS with microcytic anemia: don't be mislead by an associated condition!, PMID:39279630

Usefulness of Sarilumab in Patients with Rheumatoid Arthritis after Regression of Lymphoproliferative Disorders., PMID:39262417

Investigating the impact of Tocilizumab, Sarilumab, and Anakinra on clinical outcomes in COVID-19: A systematic review and meta-analysis., PMID:39221116

Pain Interference in Juvenile Idiopathic Arthritis., PMID:39218453

[Polymyalgia rheumatica: What's new?]., PMID:39146754

The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: A systematic review of clinical trials., PMID:39122202

Use of interleukin-6 receptor antibodies in the second and third trimester of pregnancy: a retrospective cohort study., PMID:39116898

Newer Therapies in Rheumatology., PMID:39084836

The effects of sarilumab as monotherapy and in combination with non-methotrexate disease-modifying anti-rheumatic drugs on unacceptable pain in patients with rheumatoid arthritis: A post-hoc analysis of the HARUKA phase 3 study., PMID:39073577

Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (<65 and ≥65 years): A post hoc analysis of Japanese Phase 3 clinical trials., PMID:39073574

Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study., PMID:39049740

Efficacy of sarilumab and dexamethasone co-administration for lowering multiple blood biomarkers in the treatment of cytokine release syndrome in hospitalized COVID-19 patients., PMID:39028068

Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development., PMID:38879822

Safety of sarilumab in a Japanese population with rheumatoid arthritis by age group: Data from an interim analysis of a postmarketing surveillance study., PMID:38804962

Effect of IL-6R blockade on plasma lipids and clinical outcomes among hospitalized patients with COVID-19 infection., PMID:38795859

Late Tuberculosis Reactivation After Severe Covid-19., PMID:38715882

Sarilumab (Kevzara) for polymyalgia rheumatica., PMID:38696312

COVID-19: An Update on Epidemiology, Prevention and Treatment, September-2023., PMID:38633552

Document Download

Anti-Sarilumab ELISA Kit.pdf